SpringerPlus

Table 3 Adverse events

From: A phase II, multicenter, single-arm trial of eribulin as first-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer

Adverse events	N = 35
Adverse events	Any grade [n (%)]	Grade 3/4 [n (%)]
Hematological
Neutropenia	34 (97.1)	22 (62.9)
Leucopenia	31 (88.6)	9 (25.7)
Anemia	18 (51.4)	0 (0)
Thrombocytopenia	18 (51.4)	0 (0)
Febrile neutropenia	2 (5.7)	2 (5.7)
Non-hematological
AST	29 (82.9)	1 (2.9)
ALT	29 (82.9)	0 (0)
Alopecia	26 (74.3)	NA
Fatigue	22 (62.9)	0 (0)
Sensory neuropathy	21 (60.0)	1 (2.9)
Fever	17 (48.6)	0 (0)
Mucositis	13 (37.1)	1 (2.9)
Γ-GTP	13 (37.1)	2 (5.7)
Nausea	11 (31.4)	0 (0)
Taste disturbance	11 (31.4)	0 (0)
Anorexia	10 (28.6)	0 (0)
ALP	9 (25.7)	1 (2.9)
Skin rash	6 (17.1)	1 (2.9)
Vomiting	4 (11.4)	0 (0)
Constipation	4 (11.4)	0 (0)
Diarrhea	4 (11.4)	0 (0)
Arthralgia	4 (11.4)	0 (0)
Edema	4 (11.4)	0 (0)
Myalgia	3 (6.6)	0 (0)
Motor neuropathy	2 (5.7)	0 (0)

NA not available, AST aspartate aminotransferase, ALT alanine aminotransferase, GTP gamma-glutamyl transpeptidase, ALP gamma-glutamyl transpeptidase

Back to article page